240 related articles for article (PubMed ID: 2119269)
1. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
Levy RH; Rettenmeier AW; Anderson GD; Wilensky AJ; Friel PN; Baillie TA; Acheampong A; Tor J; Guyot M; Loiseau P
Clin Pharmacol Ther; 1990 Sep; 48(3):225-35. PubMed ID: 2119269
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies.
Rettie AE; Boberg M; Rettenmeier AW; Baillie TA
J Biol Chem; 1988 Sep; 263(27):13733-8. PubMed ID: 3138238
[TBL] [Abstract][Full Text] [Related]
3. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
Tang W; Borel AG; Fujimiya T; Abbott FS
Chem Res Toxicol; 1995; 8(5):671-82. PubMed ID: 7548749
[TBL] [Abstract][Full Text] [Related]
4. Effect of valproate dose on formation of hepatotoxic metabolites.
Anderson GD; Acheampong AA; Wilensky AJ; Levy RH
Epilepsia; 1992; 33(4):736-42. PubMed ID: 1628592
[TBL] [Abstract][Full Text] [Related]
5. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE
J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388
[TBL] [Abstract][Full Text] [Related]
6. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.
Kondo T; Otani K; Hirano T; Kaneko S; Fukushima Y
Br J Clin Pharmacol; 1990 Jan; 29(1):116-9. PubMed ID: 2105099
[TBL] [Abstract][Full Text] [Related]
7. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
Tang W; Abbott FS
Drug Metab Dispos; 1997 Feb; 25(2):219-27. PubMed ID: 9029053
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
Ben-Menachem E; Gunning B; Arenas Cabrera CM; VanLandingham K; Crockett J; Critchley D; Wray L; Tayo B; Morrison G; Toledo M
CNS Drugs; 2020 Jun; 34(6):661-672. PubMed ID: 32350749
[TBL] [Abstract][Full Text] [Related]
9. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.
Contin M; Riva R; Albani F; Baruzzi AA
Ther Drug Monit; 1999 Dec; 21(6):604-8. PubMed ID: 10604819
[TBL] [Abstract][Full Text] [Related]
10. [Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients].
Chen ZJ; Wang XD; Zhou LM; Fang ZY; Wang HS; Li JL; Zhou JQ; Huang HB; Huang M
Yao Xue Xue Bao; 2014 Apr; 49(4):530-4. PubMed ID: 24974473
[TBL] [Abstract][Full Text] [Related]
11. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.
Kassahun K; Abbott F
Drug Metab Dispos; 1993; 21(6):1098-106. PubMed ID: 7905390
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes.
Surendradoss J; Chang TK; Abbott FS
Toxicol Appl Pharmacol; 2012 Nov; 264(3):413-22. PubMed ID: 22940460
[TBL] [Abstract][Full Text] [Related]
13. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
Lee MS; Lee YJ; Kim BJ; Shin KJ; Chung BC; Baek DJ; Jung BH
Arch Pharm Res; 2009 Jul; 32(7):1029-35. PubMed ID: 19641884
[TBL] [Abstract][Full Text] [Related]
14. Enantiotopic differentiation during the biotransformation of valproic acid to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid.
Porubek DJ; Barnes H; Meier GP; Theodore LJ; Baillie TA
Chem Res Toxicol; 1989; 2(1):35-40. PubMed ID: 2519229
[TBL] [Abstract][Full Text] [Related]
15. Characterization of thiol-conjugated metabolites of 2-propylpent-4-enoic acid (4-ene VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry.
Tang W; Abbott FS
J Mass Spectrom; 1996 Aug; 31(8):926-36. PubMed ID: 8799319
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat.
Singh K; Orr JM; Abbott FS
Drug Metab Dispos; 1988; 16(6):848-52. PubMed ID: 2907464
[TBL] [Abstract][Full Text] [Related]
17. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
Kassahun K; Baillie TA
Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
[TBL] [Abstract][Full Text] [Related]
19. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism.
Wietholtz H; Zysset T; Kreiten K; Kohl D; Büchsel R; Matern S
Eur J Clin Pharmacol; 1989; 36(4):401-6. PubMed ID: 2500346
[TBL] [Abstract][Full Text] [Related]
20. CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid.
Rettie AE; Sheffels PR; Korzekwa KR; Gonzalez FJ; Philpot RM; Baillie TA
Biochemistry; 1995 Jun; 34(24):7889-95. PubMed ID: 7794900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
